Renal impairment at diagnosis in myeloma

Patient characteristics, treatment, and impact on outcomes. Results from the Australia and New Zealand Myeloma and Related Diseases Registry

P. Joy Ho, Elizabeth M. Moore, Zoe K. McQuilten, Cameron Wellard, Krystal Bergin, Bradley Augustson, Hilary Blacklock, Simon J. Harrison, Noemi Horvath, Tracy King, Peter Mollee, Hang Quach, Christopher Reid, Brian Rosengarten, Patricia Walker, Erica M. Wood, Andrew Spencer

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Renal impairment (RI) is a common complication of multiple myeloma (MM) and remains a poor prognostic factor despite improved survival with newer therapies. Patients and Methods: We evaluated baseline characteristics, treatment, and outcomes of newly diagnosed MM patients with RI at diagnosis in the Australia and New Zealand Myeloma and Related Diseases Registry over 5 years to April 2018; we compared patients with RI (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2) with those with eGFR ≥60. In autologous stem cell transplantation (ASCT) analyses, patients aged 70 years and younger and ≥1 year from diagnosis were included. Results: Overall, 36% of patients with newly diagnosed MM had RI; they were older, had more advanced disease and comorbidities, and worse performance status. Bortezomib-based induction therapy was most commonly used, although administered to fewer RI patients, despite similar response rates. Patients with RI were less likely to receive ASCT; however, recipients had longer progression-free survival (PFS) and overall survival (OS). Patients with RI had shorter OS and PFS after adjusting for age. In ASCT recipients with RI versus no RI, there was no difference in PFS and OS. Conclusion: Our findings in “real world” MM patients with RI confirm that patient-, disease-, and treatment-related factors (such as suboptimal bortezomib and ASCT use), and delays in commencing therapy, might contribute to poorer outcomes, and support the use of ASCT in patients with RI.

Original languageEnglish
Number of pages10
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
Publication statusAccepted/In press - 16 May 2019

Keywords

  • Autologous
  • Multiple myeloma
  • Registry
  • Renal Impairment
  • Transplantation

Cite this

Ho, P. Joy ; Moore, Elizabeth M. ; McQuilten, Zoe K. ; Wellard, Cameron ; Bergin, Krystal ; Augustson, Bradley ; Blacklock, Hilary ; Harrison, Simon J. ; Horvath, Noemi ; King, Tracy ; Mollee, Peter ; Quach, Hang ; Reid, Christopher ; Rosengarten, Brian ; Walker, Patricia ; Wood, Erica M. ; Spencer, Andrew. / Renal impairment at diagnosis in myeloma : Patient characteristics, treatment, and impact on outcomes. Results from the Australia and New Zealand Myeloma and Related Diseases Registry. In: Clinical Lymphoma, Myeloma and Leukemia. 2019.
@article{67313474337c4a0898c5d463dc384756,
title = "Renal impairment at diagnosis in myeloma: Patient characteristics, treatment, and impact on outcomes. Results from the Australia and New Zealand Myeloma and Related Diseases Registry",
abstract = "Background: Renal impairment (RI) is a common complication of multiple myeloma (MM) and remains a poor prognostic factor despite improved survival with newer therapies. Patients and Methods: We evaluated baseline characteristics, treatment, and outcomes of newly diagnosed MM patients with RI at diagnosis in the Australia and New Zealand Myeloma and Related Diseases Registry over 5 years to April 2018; we compared patients with RI (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2) with those with eGFR ≥60. In autologous stem cell transplantation (ASCT) analyses, patients aged 70 years and younger and ≥1 year from diagnosis were included. Results: Overall, 36{\%} of patients with newly diagnosed MM had RI; they were older, had more advanced disease and comorbidities, and worse performance status. Bortezomib-based induction therapy was most commonly used, although administered to fewer RI patients, despite similar response rates. Patients with RI were less likely to receive ASCT; however, recipients had longer progression-free survival (PFS) and overall survival (OS). Patients with RI had shorter OS and PFS after adjusting for age. In ASCT recipients with RI versus no RI, there was no difference in PFS and OS. Conclusion: Our findings in “real world” MM patients with RI confirm that patient-, disease-, and treatment-related factors (such as suboptimal bortezomib and ASCT use), and delays in commencing therapy, might contribute to poorer outcomes, and support the use of ASCT in patients with RI.",
keywords = "Autologous, Multiple myeloma, Registry, Renal Impairment, Transplantation",
author = "Ho, {P. Joy} and Moore, {Elizabeth M.} and McQuilten, {Zoe K.} and Cameron Wellard and Krystal Bergin and Bradley Augustson and Hilary Blacklock and Harrison, {Simon J.} and Noemi Horvath and Tracy King and Peter Mollee and Hang Quach and Christopher Reid and Brian Rosengarten and Patricia Walker and Wood, {Erica M.} and Andrew Spencer",
year = "2019",
month = "5",
day = "16",
doi = "10.1016/j.clml.2019.05.010",
language = "English",
journal = "Clinical Lymphoma, Myeloma & Leukemia",
issn = "2152-2650",
publisher = "Elsevier",

}

Renal impairment at diagnosis in myeloma : Patient characteristics, treatment, and impact on outcomes. Results from the Australia and New Zealand Myeloma and Related Diseases Registry. / Ho, P. Joy; Moore, Elizabeth M.; McQuilten, Zoe K.; Wellard, Cameron; Bergin, Krystal; Augustson, Bradley; Blacklock, Hilary; Harrison, Simon J.; Horvath, Noemi; King, Tracy; Mollee, Peter; Quach, Hang; Reid, Christopher; Rosengarten, Brian; Walker, Patricia; Wood, Erica M.; Spencer, Andrew.

In: Clinical Lymphoma, Myeloma and Leukemia, 16.05.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Renal impairment at diagnosis in myeloma

T2 - Patient characteristics, treatment, and impact on outcomes. Results from the Australia and New Zealand Myeloma and Related Diseases Registry

AU - Ho, P. Joy

AU - Moore, Elizabeth M.

AU - McQuilten, Zoe K.

AU - Wellard, Cameron

AU - Bergin, Krystal

AU - Augustson, Bradley

AU - Blacklock, Hilary

AU - Harrison, Simon J.

AU - Horvath, Noemi

AU - King, Tracy

AU - Mollee, Peter

AU - Quach, Hang

AU - Reid, Christopher

AU - Rosengarten, Brian

AU - Walker, Patricia

AU - Wood, Erica M.

AU - Spencer, Andrew

PY - 2019/5/16

Y1 - 2019/5/16

N2 - Background: Renal impairment (RI) is a common complication of multiple myeloma (MM) and remains a poor prognostic factor despite improved survival with newer therapies. Patients and Methods: We evaluated baseline characteristics, treatment, and outcomes of newly diagnosed MM patients with RI at diagnosis in the Australia and New Zealand Myeloma and Related Diseases Registry over 5 years to April 2018; we compared patients with RI (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2) with those with eGFR ≥60. In autologous stem cell transplantation (ASCT) analyses, patients aged 70 years and younger and ≥1 year from diagnosis were included. Results: Overall, 36% of patients with newly diagnosed MM had RI; they were older, had more advanced disease and comorbidities, and worse performance status. Bortezomib-based induction therapy was most commonly used, although administered to fewer RI patients, despite similar response rates. Patients with RI were less likely to receive ASCT; however, recipients had longer progression-free survival (PFS) and overall survival (OS). Patients with RI had shorter OS and PFS after adjusting for age. In ASCT recipients with RI versus no RI, there was no difference in PFS and OS. Conclusion: Our findings in “real world” MM patients with RI confirm that patient-, disease-, and treatment-related factors (such as suboptimal bortezomib and ASCT use), and delays in commencing therapy, might contribute to poorer outcomes, and support the use of ASCT in patients with RI.

AB - Background: Renal impairment (RI) is a common complication of multiple myeloma (MM) and remains a poor prognostic factor despite improved survival with newer therapies. Patients and Methods: We evaluated baseline characteristics, treatment, and outcomes of newly diagnosed MM patients with RI at diagnosis in the Australia and New Zealand Myeloma and Related Diseases Registry over 5 years to April 2018; we compared patients with RI (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2) with those with eGFR ≥60. In autologous stem cell transplantation (ASCT) analyses, patients aged 70 years and younger and ≥1 year from diagnosis were included. Results: Overall, 36% of patients with newly diagnosed MM had RI; they were older, had more advanced disease and comorbidities, and worse performance status. Bortezomib-based induction therapy was most commonly used, although administered to fewer RI patients, despite similar response rates. Patients with RI were less likely to receive ASCT; however, recipients had longer progression-free survival (PFS) and overall survival (OS). Patients with RI had shorter OS and PFS after adjusting for age. In ASCT recipients with RI versus no RI, there was no difference in PFS and OS. Conclusion: Our findings in “real world” MM patients with RI confirm that patient-, disease-, and treatment-related factors (such as suboptimal bortezomib and ASCT use), and delays in commencing therapy, might contribute to poorer outcomes, and support the use of ASCT in patients with RI.

KW - Autologous

KW - Multiple myeloma

KW - Registry

KW - Renal Impairment

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=85067210337&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2019.05.010

DO - 10.1016/j.clml.2019.05.010

M3 - Article

JO - Clinical Lymphoma, Myeloma & Leukemia

JF - Clinical Lymphoma, Myeloma & Leukemia

SN - 2152-2650

ER -